ALNY Intrinsic Valuation and Fundamental Analysis - Alnylam Pharmaceuticals Inc - Alpha Spread

Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 255.23 USD 3.42% Market Closed
Market Cap: 32.2B USD
Have any thoughts about
Alnylam Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one ALNY stock under the Base Case scenario is 167.29 USD. Compared to the current market price of 255.23 USD, Alnylam Pharmaceuticals Inc is Overvalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALNY Intrinsic Value
167.29 USD
Overvaluation 34%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
How do you feel about ALNY?
Bearish
Neutral
Bullish

Valuation Backtest
Alnylam Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ALNY based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Alnylam Pharmaceuticals Inc

Provide an overview of the primary business activities
of Alnylam Pharmaceuticals Inc.

What unique competitive advantages
does Alnylam Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Alnylam Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Alnylam Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Alnylam Pharmaceuticals Inc.

What significant events have occurred
in Alnylam Pharmaceuticals Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Alnylam Pharmaceuticals Inc.

Provide P/S
for Alnylam Pharmaceuticals Inc.

Provide P/E
for Alnylam Pharmaceuticals Inc.

Provide P/OCF
for Alnylam Pharmaceuticals Inc.

Provide P/FCFE
for Alnylam Pharmaceuticals Inc.

Provide P/B
for Alnylam Pharmaceuticals Inc.

Provide EV/S
for Alnylam Pharmaceuticals Inc.

Provide EV/GP
for Alnylam Pharmaceuticals Inc.

Provide EV/EBITDA
for Alnylam Pharmaceuticals Inc.

Provide EV/EBIT
for Alnylam Pharmaceuticals Inc.

Provide EV/OCF
for Alnylam Pharmaceuticals Inc.

Provide EV/FCFF
for Alnylam Pharmaceuticals Inc.

Provide EV/IC
for Alnylam Pharmaceuticals Inc.

Show me price targets
for Alnylam Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Alnylam Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Alnylam Pharmaceuticals Inc?

What are the Net Income projections
for Alnylam Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Alnylam Pharmaceuticals Inc?

What are the EPS projections
for Alnylam Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Alnylam Pharmaceuticals Inc?

What are the EBIT projections
for Alnylam Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Alnylam Pharmaceuticals Inc?

Compare the revenue forecasts
for Alnylam Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Alnylam Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Alnylam Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Alnylam Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Alnylam Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Alnylam Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Alnylam Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Alnylam Pharmaceuticals Inc.

Provide ROE
for Alnylam Pharmaceuticals Inc.

Provide ROA
for Alnylam Pharmaceuticals Inc.

Provide ROIC
for Alnylam Pharmaceuticals Inc.

Provide ROCE
for Alnylam Pharmaceuticals Inc.

Provide Gross Margin
for Alnylam Pharmaceuticals Inc.

Provide Operating Margin
for Alnylam Pharmaceuticals Inc.

Provide Net Margin
for Alnylam Pharmaceuticals Inc.

Provide FCF Margin
for Alnylam Pharmaceuticals Inc.

Show all solvency ratios
for Alnylam Pharmaceuticals Inc.

Provide D/E Ratio
for Alnylam Pharmaceuticals Inc.

Provide D/A Ratio
for Alnylam Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Alnylam Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Alnylam Pharmaceuticals Inc.

Provide Quick Ratio
for Alnylam Pharmaceuticals Inc.

Provide Current Ratio
for Alnylam Pharmaceuticals Inc.

Provide Cash Ratio
for Alnylam Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Alnylam Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Alnylam Pharmaceuticals Inc?

What is the current Free Cash Flow
of Alnylam Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Alnylam Pharmaceuticals Inc.

Business Breakdown

Alnylam Pharmaceuticals Inc. is at the forefront of transforming the landscape of genetic medicine through its pioneering work in RNA interference (RNAi) technology. Founded in 2002, the company embarked on a bold mission to develop innovative therapies for rare and challenging diseases caused by genetic mutations. By leveraging the power of RNAi, Alnylam enables the silencing of specific disease-causing genes, offering a potential cure rather than just symptomatic relief. Their flagship products, like Onpattro and GIVLAARI, have already gained approval for treating debilitating conditions such as hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria, making waves in the...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Alnylam Pharmaceuticals Inc

Current Assets 3.2B
Cash & Short-Term Investments 2.6B
Receivables 309.5m
Other Current Assets 238.7m
Non-Current Assets 836.8m
PP&E 715.5m
Other Non-Current Assets 121.3m
Current Liabilities 1.1B
Accounts Payable 74m
Accrued Liabilities 850.3m
Other Current Liabilities 131m
Non-Current Liabilities 3B
Long-Term Debt 1B
Other Non-Current Liabilities 1.9B
Efficiency

Earnings Waterfall
Alnylam Pharmaceuticals Inc

Revenue
2.3B USD
Cost of Revenue
-304.8m USD
Gross Profit
2B USD
Operating Expenses
-1.9B USD
Operating Income
102.7m USD
Other Expenses
-175.6m USD
Net Income
-72.9m USD

Free Cash Flow Analysis
Alnylam Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 2024, Alnylam Pharmaceuticals achieved a 34% year-over-year increase in global net product revenues, reaching $410 million, driven by a 37% rise in the transthyretin (TTR) business. The company raised its full-year revenue guidance by 11% at the midpoint, anticipating net product revenues between $1.575 billion and $1.65 billion. Key highlights include positive HELIOS-B Phase III results for vutrisiran, showing a 35%-36% mortality benefit and potential as a new standard for ATTR cardiomyopathy, pending regulatory approval. Their pipeline remains strong with plans for 15 new INDs by end of 2025, setting the stage for sustained growth and innovation .

What is Earnings Call?
Fundamental Scores

ALNY Profitability Score
Profitability Due Diligence

Alnylam Pharmaceuticals Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional 1-Year Revenue Growth
ROE is Increasing
43/100
Profitability
Score

Alnylam Pharmaceuticals Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

ALNY Solvency Score
Solvency Due Diligence

Alnylam Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Negative Net Debt
Average Altman Z-Score
55/100
Solvency
Score

Alnylam Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast ALNY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALNY is 291.87 USD with a low forecast of 162.11 USD and a high forecast of 420 USD.

Lowest
Price Target
162.11 USD
36% Downside
Average
Price Target
291.87 USD
14% Upside
Highest
Price Target
420 USD
65% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ALNY?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for ALNY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about ALNY dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

ALNY Price
Alnylam Pharmaceuticals Inc

1M 1M
-5%
6M 6M
+71%
1Y 1Y
+25%
3Y 3Y
+35%
5Y 5Y
+209%
10Y 10Y
+288%
Annual Price Range
255.23
52w Low
143.31
52w High
287.01
Price Metrics
Average Annual Return 30.17%
Standard Deviation of Annual Returns 13.13%
Max Drawdown -15%
Shares Statistics
Market Capitalization 32.7B USD
Shares Outstanding 126 000 000
Percentage of Shares Shorted 4.04%

Competitive Landscape

Ownership

ALNY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ALNY News

Other Videos

Profile

Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

32.7B USD

Dividend Yield

0%

Description

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1,665 full-time employees. The company went IPO on 2004-05-28. The company is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.

Contact

MASSACHUSETTS
Cambridge
675 W Kendall St
+16175518200.0
www.alnylam.com

IPO

2004-05-28

Employees

1 665

Officers

See Also

Discover More
What is the Intrinsic Value of one ALNY stock?

The intrinsic value of one ALNY stock under the Base Case scenario is 167.29 USD.

Is ALNY stock undervalued or overvalued?

Compared to the current market price of 255.23 USD, Alnylam Pharmaceuticals Inc is Overvalued by 34%.

Back to Top